![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, May 06, 2017 12:06:56 PM
Per last presentation, they assured investors they would have funded TyrNovo with KIT-302's license agreements.
This first SK deal didn't give them upfront. I think EU and US deals will be a game changer for them in term of cash and confidence.
I have now no doubt of Dexcel's interest in KIT-302. Will they partner it in EU? For sure it will be the best EU deal for them. Dexcel ( http://www.dexcel.com/dexcel-in-numbers/ ) is one of the largest Isreali's pharmaceuticals company. Don't forget they have the right for first negotiation for KIT-302. And Who will partner it in US? Upfront payments have to be huge in order to avoid dilution in the near term. As of December 31 2016, they have approx $15mm in cash with approx $6mm in annualized cash burn.
Still no premium to the pipeline. Market wants to see KIT-302 NDA filing\Acceptance.
EnricoMania
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • ELMGF • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM